ArticleTheranostics2019
Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
10.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025.Endocrine journal · 2026Guideline
- Biomarkers of metastatic disease in pheochromocytoma and paraganglioma.Endocrine connections · 2026Article
- Overcoming mTOR Inhibitor Resistance: From Biological Basis to Therapeutic Strategies.Biomedicines · 2026Review
- Multi-omics insights into metastatic pheochromocytomas and paragangliomas: Mechanisms, signatures, and prediction models.Hormones (Athens, Greece) · 2026Review
- Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management.Insights into imaging · 2026Article
- The Perioperative Biochemical and Clinical Considerations of Pheochromocytoma Management.International journal of molecular sciences · 2025Review
- Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles.Nature communications · 2025Article
- Molecular roles of microRNA-21 and exosomal miR-21 in gastrointestinal cancers: diagnostic, therapeutic, and drug resistance insights.Frontiers in molecular biosciences · 2025Review
- FAM117A and PIGU regulate the trilogy of gastric carcinogenesis.Computational and structural biotechnology journal · 2025Article
- Circulating non-coding RNA biomarkers of endocrine tumours.Nature reviews. Endocrinology · 2024Review
- Genetic and Molecular Biomarkers in Aggressive Pheochromocytomas and Paragangliomas.International journal of molecular sciences · 2024Review
- From diagnosis to resistance: a symphony of miRNAs in pheochromocytoma progression and treatment response.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Proteomic characterization of head and neck paraganglioma and its molecular classification.Frontiers in molecular neuroscience · 2024Article
- Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments.Theranostics · 2024Review
- Image-Guided Precision Medicine in the Diagnosis and Treatment of Pheochromocytomas and Paragangliomas.Cancers · 2023Review
- MicroRNAs associated with postoperative outcomes in patients with limited stage neuroendocrine carcinoma of the esophagus.Oncology letters · 2023Article
- Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma.Nature communications · 2023Article
- MicroRNA Expression Profile in TSC Cell Lines and the Impact of mTOR Inhibitor.International journal of molecular sciences · 2022Article
- Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome.Nature reviews. Clinical oncology · 2022Review
- The Role of the Metabolome and Non-Coding RNA on Pheochromocytomas and Paragangliomas: An Update.Metabolites · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors at 17 institutions in 6 countries.
Bruna CalsinaHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Luis Jaime Castro-VegaINSERM, UMR970, Paris-Cardiovascular Research Center, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.
Rafael Torres-PérezHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Lucía Inglada-PérezHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Maria Currás-FreixesHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Juan María Roldán-RomeroHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Veronika MancikovaHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Rocío LetónHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Laura RemachaHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
María SantosHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Nelly BurnichonINSERM, UMR970, Paris-Cardiovascular Research Center, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.
Charlotte Lussey-LepoutreINSERM, UMR970, Paris-Cardiovascular Research Center, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.
Elena RapizziDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Osvaldo GrañaBioinformatics Unit, Structural Biology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Cristina Álvarez-EscoláServicio de Endocrinología y Nutrición, Hospital Universitario La Paz, Madrid, Spain.
Aguirre A de CubasHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Javier LanillosHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Alfonso Cordero-BarrealHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Ángel M Martínez-MontesHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Alexandre BellucciAssistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Radiologie, Paris, France.
Laurence AmarINSERM, UMR970, Paris-Cardiovascular Research Center, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.
Fabio Luiz Fernandes-RosaINSERM, UMR970, Paris-Cardiovascular Research Center, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.
María CalatayudDepartment of Endocrinology and Nutrition Service, Hospital Universitario 12 de Octubre, Madrid, Spain.
Javier AllerDepartment of Endocrinology, Puerta de Hierro University Hospital, Madrid, Spain.
Cristina LamasDepartment of Endocrinology, Albacete University Hospital Complex, Albacete, Spain.
Júlia Sastre-MarcosDepartment of Endocrinology, Virgen de la Salud Hospital-Toledo Hospital Complex, Toledo, Spain.
Letizia CanuDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Esther KorpershoekDepartment of Pathology, Erasmus Medical Center Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Henri J TimmersDepartment of Internal Medicine, Radboud University Medical Centre, 6525 HP Nijmegen, The Netherlands.
Jacques Wm LendersDepartment of Internal Medicine, Radboud University Medical Centre, 6525 HP Nijmegen, The Netherlands.
Felix BeuschleinMedizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany.
Martin Fassnacht-CapellerDepartment of Internal Medicine I, Endocrine and Diabetes Unit, University Hospital Würzburg, University of Würzburg, Germany.
Graeme EisenhoferInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Massimo MannelliDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Fátima Al-ShahrourBioinformatics Unit, Structural Biology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Judith FavierINSERM, UMR970, Paris-Cardiovascular Research Center, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.
Cristina Rodríguez-AntonaHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Alberto CascónHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Cristina Montero-CondeHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Anne-Paule Gimenez-RoqueploINSERM, UMR970, Paris-Cardiovascular Research Center, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.
Mercedes RobledoHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Spanish National Cancer Research Centre · ESUniversity of Florence · ITCentro de Investigación Biomédica en Red · ESDélégation Paris 5 · FRRadboud University Medical Center · NLCentre for Biomedical Network Research on Rare Diseases · ESErasmus MC Cancer Institute · NLHôpital Européen · FRHospital Universitario La Paz · ESHospital Universitario Puerta de Hierro Majadahonda · ESParis Cardiovascular Research Center · FRSorbonne Paris Cité · FRSorbonne Université · FRTU Dresden · DEUniversité Paris Cité · FRUniversity Hospital of Zurich · CHUniversity of Würzburg · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
TranscriptomeBiomarkers, TumorBrain NeoplasmsCell Line, TumorGene Expression Regulation, NeoplasticHumansMicroRNAsNeoplasm MetastasisParagangliomaTOR Serine-Threonine KinasesTuberous Sclerosis Complex 2 ProteinTumor Cells, CulturedBiomarkers, TumorMicroRNAsMIRN21 microRNA, humanTOR Serine-Threonine KinasesTSC2 protein, humanTuberous Sclerosis Complex 2 Proteinliquid biopsymiR-21-3pmulti-omic integrationpheochromocytoma/paragangliomaprognostic biomarker
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.